Ligand Pharmaceuticals has agreed to acquire fellow San Diego-based biotech Metabasis Therapeutics in a US$3.2 M deal. Substantial and important programmes in hepatitis B, liver cancer, type 2 diabetes and high cholesterol, which were at risk of sinking due to Metabasis’ financial woes, have now got a fresh lease of life.